HeartFlow Earns a Top Position in Artificial Intelligence for 2019
REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow,
Inc., a medical technology company uniquely positioned at the
intersection of advanced artificial intelligence (AI) capabilities and
healthcare, today announced it has been named to Fast Company’s
prestigious annual list of the World’s
Most Innovative Companies for 2019. The list honors the businesses
making the most profound impact on both industry and culture.
HeartFlow is recognized in the Artificial Intelligence category for the HeartFlow
Analysis, a non-invasive, cardiac test that leverages deep learning,
a form of AI, combined with the efforts of highly trained human analysts
to create a personalized 3D model of the heart. It applies advanced
algorithms to solve millions of complex equations to assess the impact
of blockages on blood flow to the heart, helping physicians visualize
the problem and determine the best treatment pathway for each patient.
With the HeartFlow Analysis, HeartFlow is driving towards a new standard
of care for the diagnosis and treatment of heart disease – the number
one killer worldwide according to the Centers
for Disease Control.
The HeartFlow technology has been demonstrated to significantly reduce
unnecessary and invasive diagnostic coronary angiography procedures,
which can be associated with bleeding, stroke, major blood vessel damage
and other serious complications. By non-invasively identifying which
patients do and do not need intervention, clinicians can reduce
unnecessary invasive testing, reduce healthcare system costs and improve
patient quality of life.1 To date, clinicians have used the
HeartFlow Analysis for more than 30,000 patients to aid in the diagnosis
of heart disease.
“At HeartFlow, we’re taking the best of cutting-edge technology and
applying it to help physicians save lives,” said John H. Stevens, M.D.,
president and chief executive officer of HeartFlow. “We’ve only just
scratched the surface of the tremendous potential of AI in healthcare
and we’re eager to bring our innovative approach to diagnosing and
treating heart disease to the world.”
About HeartFlow, Inc.
HeartFlow, Inc. is a medical technology company redefining the way heart
disease is diagnosed and treated. Our non-invasive HeartFlow FFRct
Analysis leverages deep learning to create a personalized 3D model of
the heart. By using this model, clinicians can better evaluate the
impact a blockage has on blood flow and determine the best treatment for
patients. Our technology is reflective of our Silicon Valley roots and
incorporates decades of scientific evidence with the latest advances in
artificial intelligence. The HeartFlow FFRct Analysis is commercially
available in the United States, Canada, Europe and Japan. For more
information, visit www.heartflow.com.
About Fast Company
Fast Company is the only media brand fully dedicated to the vital
intersection of business, innovation, and design, engaging the most
influential leaders, companies and thinkers on the future of business.
Since 2011, Fast Company has received some of the most prestigious
editorial and design accolades, including the American Society of
Magazine Editors (ASME) National Magazine Award for “Magazine Of The
Year,” Adweek’s Hot List for “Hottest Business Publication,” and six
gold medals and 10 silver medals from the Society of Publication
Designers. The editor-in-chief is Stephanie Mehta and the publisher is
Amanda Smith. Headquartered in New York City, Fast Company is published
by Mansueto Ventures LLC, along with our sister publication Inc., and
can be found online at www.fastcompany.com.
1 Douglas PS, DeBruyne B, Pontone G., Patel MR, et al.
One-year outcomes of FFRCT-guided care in patients with suspected
coronary disease: The PLATFORM Study. J Am Coll Cardiol.